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 Abstract 21 
The impact of Pneumocystis pneumonia (PcP) on morbidity and mortality remains substan-22 
tial for immunocompromised individuals, including those afflicted by HIV infection, organ 23 
transplantation, cancer, auto-immune diseases, or subject to chemotherapy or corticoster-24 
oid-based therapies. Previous work from our group has shown that repurposing antimalarial 25 
compounds for PcP holds promise for treatment of this opportunistic infection. Following 26 
our previous discovery of chloroquine analogues with dual-stage antimalarial action both in 27 
vitro and in vivo, we now report the potent action of these compounds on Pneumocystis 28 
carinii, in vitro. Identification of chloroquine analogues as anti-PcP leads is an unprece-29 
dented finding. 30 
 31 
Introduction 32 
Pneumocystis jirovecii pneumonia (PcP) is a potentially fatal opportunistic infection for 33 
immunocompromised individuals, such as those infected with HIV, or receiving immuno-34 
suppressive therapies for organ transplantation, cancer or autoimmune diseases. (1-3) De-35 
spite fatality rates due to PcP in HIV-infected people have significantly dropped due to 36 
highly active antiretroviral therapies (HAART), PcP remains a major cause of death or of 37 
chronic lung dysfunction amongst people affected by diseases as diverse as lymphoma,(4) 38 
rheumatoid arthritis,(5) lupus erythematosus,(6) or renal dysfunction due to IgA nephropa-39 
thy.(7) Moreover, atypical radiological presentation of PcP sometimes occur, leading to 40 
delayed diagnosis and intervention, with frequently discouraging end results.(1,7) Though 41 
considered as an innocuous infection in  immunocompetent people, P. jirovecii has been 42 
suggested as a morbidity factor in sudden infant death syndrome, given its high incidence in 43 
healthy infants.(8) 44 
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 P. jirovecii, formerly known P. carinii f. sp. hominis, is the causative agent of PcP or pneu-45 
mocystosis in humans, and was originally identified as the pathogen responsible for the 46 
epidemics of interstitial plasma cell pneumonitis that infected premature infants in Europe 47 
during World War II.(2,9) Pneumocystis spp. are unicellular eukaryotic organisms now in-48 
cluded in the Fungi kingdom, due to their high genetic homology with other fungi.(2,10) 49 
These fungi are thought to be host-specific and infect a wide variety of mammals.(11) P. 50 
jirovecii infects humans, while P. carinii and P. murina infect rats and mice, respectively. 51 
Pre-clinical drug screening is conducted using the latter two species, as a culture system to 52 
properly propagate P. jirovecii in vitro was developed only recently, and still requires vali-53 
dation.(12)  54 
Pneumocystis spp. have several features that are atypical amongst fungi, such as the lack of 55 
efficacy of common anti-fungal agents like amphotericin B and the ketoconazoles, likely 56 
due to the lack of ergosterol as the major sterol in their membranes.(13) Initially, these mi-57 
croorganisms were thought to be protozoans, as they were susceptible to antiprotozoals like 58 
primaquine, trimethoprim, sulfa drugs, pentamidine, or atovaquone, among others; these are 59 
still present in anti-PcP therapies, where the recommended first-line regimen for PcP 60 
prophylaxis and treatment is the well-known trimethoprim/sulfamethoxazole (TMP-SMX) 61 
combination, used for more than 50 years as a wide-spectrum antibiotic, and also employed 62 
against malaria.(13,14)   63 
Some reports documenting P. jirovecii gene mutations in the target of the sulfamethoxazole 64 
component, dihydropteroate synthase, (15,16) may indicate resistance of this pathogen to 65 
TMP-SMX, supporting earlier reports.(17-19) Alternative options for salvage therapy in-66 
clude intravenous pentamidine, whose adverse effects are usually worse than those of TMP-67 
SMX, or primaquine/clindamycin combinations.(20) Clinical use of the latter still lacks 68 
 o
n
 Septem
ber 11, 2018 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
 approval in several countries, partly because primaquine (PQ, 1) is hemotoxic, in particular 69 
for people with 6-glucose-phosphate dehydrogenase (6GPD).(21,22)  70 
As hemotoxicity and low oral bioavailiability are major downsides of PQ’s use in the clini-71 
cal practice, we have been working on its chemical modification over the past decade, in an 72 
attempt to improve its action on malaria,(23-28) leishmaniasis,(29,30) and pneumocysto-73 
sis,(24,25) with overall promising results. These successes provided the rationale to extend 74 
such “chemical recycling” efforts to other antimalarials, as chloroquine (CQ, 2 in Fig. 75 
1),(31,32) and mepacrine (MPR, 3 in Figure 1).(32) This effort delivered N-acyl chloro-76 
quine analogues (2a-j in Figure 1) as relevant antiparasitic leads, active against liver and 77 
blood-stage Plasmodia,(31,32) as well as Leishmania parasites,(28) while being generally 78 
non-cytotoxic.(31,32) Moreover, one of such leads, 2c, displayed remarkable in vivo per-79 
formance in immunocompetent mice, when encapsulated in immunoPEGliposomes specifi-80 
cally targeted at Plasmodium-infected erythrocytes (PiRBC).(33)  81 
In view of the above, we have now investigated the anti-Pneumocystis activity of N-acyl 82 
chloroquine derivatives 2a-j (Fig. 1) using a standardized in vitro assay with P. carinii.(34) 83 
The study included N-acyl primaquine and N-acyl mepacrine analogues, 1a,b and 3a, re-84 
spectively, as well as all relevant parent antimalarials, for comparison (see Figure 1). The 85 
effects of replacing the covalent amide bond between the antimalarial pharmacophore and 86 
the cinnamoyl group in PQ derivatives 1a,b and CQ derivatives 2a,d, by an ionic ammoni-87 
um carboxylate bond, respectively producing PQ-derived ionic liquids 1’a,b,(26) and CQ-88 
derived ionic liquids 2’a,d (Figure 1), were also assessed. 89 
 90 
[insert Figure 1 here] 91 
 92 
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 Results 93 
Chemical synthesis. The test compounds were prepared with a minimum 95% purity as 94 
described elsewhere and presented structural data consistent with previous re-95 
ports.(27,31,32) Novel ionic liquids 2’a,d, were successfully synthesized and presented 96 
adequate purity and spectral data, as given in detail under Materials&Methods. 97 
Anti-Pneumocystis activity and cytotoxicity assays. All the test compounds (including 98 
parent drugs 1-3) were first screened for their anti-Pneumocystis activity at 100 g/mL (not 99 
shown); remarkably, with exception of PQ derivatives 1a,b and 1’b, and of CQ derivative 100 
2h, all compounds reduced P. carinii viability (ATP content) by at least 94% after 24 h, and 101 
reached nearly 100% reduction after 72 h. Such potent anti-Pneumocystis activity of most 102 
compounds was confirmed by subsequent determination of their respective IC50 values at 103 
72 h, as shown in Table 1, which includes the compounds’ toxicity for two mammalian cell 104 
lines (equally expressed as IC50 at 72 h), namely, A549 human lung adenocarcinoma and L2 105 
rat pulmonary epithelial cells. 106 
 107 
[insert Table 1 here] 108 
 109 
Interestingly, despite the fact that, in most cases, activity differences are not markedly sig-110 
nificant within experimental error, the following trends for structure-activity relationships 111 
(SAR) were apparent:112 
 113 
(i) the anti-Pneumocystis activity of PQ (1) is markedly decreased upon N-acylation of the 114 
drug’s primary amine with a cinnamoyl group, as in 1a,b; in turn, when the amide bond 115 
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 between PQ and the cinnamic acid building blocks is replaced by a non-covalent ionic 116 
bond, as in 1’a,b, the activity of the parent drug is restored; 117 
 118 
(ii) in contrast with the previous situation, the moderate anti-Pneumocystis activity of CQ 119 
(2) is preserved or even improved in the respective N-acyl analogues, except when a flexi-120 
ble alkyl spacer between the 4-aminoquinoline core and the N-acyl group is absent, as in 121 
2h; moreover, replacement of the amide bond as in 2a,d by its ammonium carboxylate ionic 122 
counterpart, as in 2’a,d, does not affect activity expressively; 123 
(iii) within the subset of CQ analogues 2a-g, compounds 2b (R = Me) and 2d (R = OMe) 124 
are markedly more active than the others, with 2b being non-toxic to both mammalian cell 125 
lines tested; IC50 values for this subset suggest that:  126 
(a) the ideal length spacer between the 4-aminoquinoline core and the cinnamoyl 127 
group is butyl (n=4), as activity slightly drops when this length is either decreased (2b vs. 128 
2f) or increased (2d vs. 2g); notably, this was equally observed regarding anti-malarial ac-129 
tivity;(31)  130 
(b) there seems to be no obvious correlation between compounds’ lipophilicity 131 
(clogP values, not shown) and anti-Pneumocystis activity, whereas former observations 132 
regarding the antimalarial activity of these compounds indicated that more lipophilic ones 133 
seemed preferred;(31,35)  134 
(c) the influence of the stereoelectronic properties of the p-substituent R on the anti-135 
Pneumocystis activity of compounds 2a-e was also surveyed, by searching possible correla-136 
tions between IC50 values and classical descriptors, namely, Hammett constant para, induc-137 
tive sigma constant I, Charton’s sterical constant , Taft sterical parameter Es, hydropho-138 
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 bicity parameter , and molar refractivity, MR;(36) interestingly, as shown in Figure 2, a 139 
linear correlation (r2 = 0.96) seems to exist with the Hammett’s constant para, where the 140 
positive slope of the linear fit suggests that electrodonating R groups favor anti-141 
Pneumocystis activity; 142 
 143 
(iv) replacement of the aryl group (2a) by a non-aromatic cyclohexyl (2i) or propyl (2j) 144 
seems to slightly decrease activity, while improving selectivity as compared to the rest of 145 
the 2a-g series, except when it comes to the best overall performer (activity plus selectivi-146 
ty), 2b. MPR (3) and its N-acyl analogue 3a were included in this study only for compari-147 
son, as MPR was earlier reported as having low in vivo efficacy against Pneumocystis;(37) 148 
indeed, despite its marked activity, MPR was too toxic, whereas 3a was not, but still did not 149 
outshine the activity and safety performance of its CQ counterparts 2b,d.  150 
[insert Figure 2 here] 151 
Finally, all covalent compounds herein reported were run through the following publicly 152 
available filters for Pan Assay Interference Compounds (PAINS),(38) namely, ZINC 153 
(http://zinc15.docking.org/patterns/home),(39) PAINS Remover 154 
(http://www.cbligand.org/PAINS/),(40) and Aggregator Advisor 155 
(http://advisor.docking.org),(41) for identification of potential PAINS and aggregators. With 156 
the exception of compounds 3 and 3a, whose aminoacridine moiety triggered a PAINS 157 
alert,(39,40) and 2h, whose structural similarity to reported aggregators has been identi-158 
fied,(39,41) all compounds passed all filters used. In the case of organic salts 1’a, 1’b, 2’a 159 
and 2’d, only ZINC was apparently able to conveniently process their ionic structures, re-160 
turning no PAINS or aggregator alerts.161 
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8 
Discussion 162 
Globally, IC50 values against P. carinii (Table 1) confirm that, with exception of 1a,b 163 
(slightly active) and of 2h (inactive), all test compounds range from moderately to marked-164 
ly active, particularly in the cases of CQ analogues 2b,d and of MPR (3) and its analogue 165 
3a. Moreover, the vast majority of the compounds displayed only mild or no cytotoxic ac-166 
tivity against both mammalian cell lines used, being the only exceptions compounds 2a, 2c, 167 
2e, and 3, which displayed IC50 values below 10 g/mL against A549 human lung carcino-168 
ma cells. Remarkably, one of the most active compounds against P. carini, 2b, was also the 169 
most selective. 170 
Altogether, the above observations show that, in contrast to PQ, whose well-known anti-171 
Pneumocystis activity is practically lost upon acylation of the drug’s aliphatic amine, N-acyl 172 
chloroquine analogues, especially those embedding a cinnamoyl group, are quite promising 173 
anti-PcP leads. Interestingly, this is not the first time that N-cinnamoyl chloroquine ana-174 
logues like 2a-g perform surprisingly well against pathogens, e.g. P. carinii as herein de-175 
scribed, or specific pathogen developmental stages, e.g. liver-stage Plasmodia as previously 176 
reported by us,(31) for which PQ, not CQ, was one of the gold standards.  177 
The significant activity of the test compounds against Pneumocystis carinii may be differ-178 
ent against P. jirovecii or P. murina, given the biological divergence amongst these species. 179 
Still, the predictive value of in vitro methods herein applied has been previously validated 180 
in vivo on the mouse model of Pneumocystis pneumonia.(42-44) 181 
In conclusion, N-cinnamoyl chloroquine analogues like 2a-g are a notable family of anti-182 
infective compounds, in particular because they have been revealing remarkable activity on 183 
pathogens against which CQ itself, or other related compounds, have not been currently 184 
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9 
considered as useful. In the particular case of PcP, these compounds hold great promise, and 185 
best performers 2a,b will be taken forward for in vivo assays. To the best of our knowledge, 186 
unveiling CQ analogues as potent anti-PcP leads is unprecedented. 187 
Ongoing work is addressing evaluation of the potential activity of these CQ analogues 188 
against another concerning class of lung pathogens, Mycobacteria,(45) as CQ itself has 189 
been reported as potentially useful in the fight against these bacteria.(46) Results will be 190 
timely reported.  191 
 192 
Materials&Methods 193 
Chemical Synthesis. Chemicals and Instrumentation. Primaquine and chloroquine biphos-194 
phates, as well as mepacrine hydrochloride, were from Sigma-Aldrich. Cinnamic acids 195 
were all from Acros Organics. The coupling agent 2-(1H-benzotriazole-1-yl)-1,1,3,3-196 
tetramethylaminium tetrafluoroborate (TBTU) was from Bachem, and all other chemicals 197 
were from Sigma-Aldrich. All solvents were of analytical grade, and purchased to VWR 198 
International. NMR analyses were carried out on a Brucker Avance III 400 MHz spectrome-199 
ter, and samples were prepared in either deuterated chloroform (CDCl3) or deuterated 200 
dimetylsulfoxide ((CD3)2SO) with tetramethylsilane (TMS) as an internal reference. Chem-201 
ical shifts are reported downfield in parts per million (ppm) and multiplicity of proton sig-202 
nals is indicated as s (singlet), d (doublet), dd (double doublet), t (triplet), m (unresolved 203 
multiplet). High resolution mass spectra (HRMS) were obtained on an LTQ Orbitrap XL / 204 
LTQ Tune Plus 2.5.5 spectrometer, and processed with the 2.1.0 Xcalibur software (Thermo 205 
Scientific). Compounds purity was based on peak areas obtained through HPLC analyses 206 
that were run using the following conditions: 0−100% of B in A (A = H2O with 0.05% of 207 
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10 
trifluoroacetic acid; B = acetonitrile) in 30 min with a flow rate of 1 mL/min on a Merck-208 
Hitachi Lachrom Elite instrument equipped with a diode array detector (DAD) and thermo-209 
stated (Peltier effect) autosampler, using a Purospher STAR RP-18e column (150 mm × 4.0 210 
mm; particle size, 5 μm).  211 
Synthesis of primaquine derivatives 1a,b and 1’a,b. N-cinnamoyl-primaquine derivatives 212 
1a,b were prepared by previously described methods, and their analytical and structural 213 
data were consistent with those formerly reported.(27) Similarly, the synthesis of the ionic 214 
counterparts of 1a and 1b, respectively, ionic liquids 1’a and 1’b, was carried out as report-215 
ed earlier, and compounds’ structural and analytical data concurred with those hitherto pub-216 
lished.(28)  217 
Synthesis of N-acyl-chloroquine (2a-j) and of N-acyl-mepacrine (3a) analogues. The chem-218 
ical synthesis of compounds 2a-j and 3a followed similar and previously reported proce-219 
dures, yielding the expected compounds whose structural and analytical data agreed with 220 
those earlier described.(31,32,35,36,47) 221 
Synthesis of the new chloroquine/cinnamic acid-derived ionic liquids 2’a,d. Organic salts 222 
2’a,d, representative of the ionic counterparts of compounds 2a-g, were prepared as fol-223 
lows. Chloroquine was first obtained as a free base, by addition of triethylamine (0.25 mL) 224 
to a suspension of chloroquine biphosphate (0.1298 g; 0.285 mol) in dichloromethane (4 225 
mL). The mixture was stirred for 30 minutes in ice and in the dark, after which the organic 226 
layer was washed with water (3×10 mL), dried over anhydrous sodium sulfate, and evapo-227 
rated to dryness under reduced pressure. Free chloroquine base, thus quantitatively obtained 228 
as a pale yellow oil, was next dissolved in methanol, and titrated with an equimolar amount 229 
of the relevant cinnamic acid, upon dropwise addition of a methanolic solution of the acid. 230 
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11 
The neutralization reaction proceeded in the dark at room temperature for 30 minutes, after 231 
which methanol was removed by evaporation at reduced pressure and target organic salts 232 
2’a,d obtained as chromatographically homogeneous colorless viscous liquids, whose spec-233 
tral data were in agreement with the target structures, as follows. 234 
2-((7-chloroquinolin-4-yl)amino)-N,N-diethylpropan-1-aminium cinnamate (2’a) 235 
Colorless oil (51 mg, 81%) δH (400 MHz, DMSO-d6) 8.37 (s, 1H), 8.35 (d, 1H, J=4.4 Hz), 236 
7.76 (d, 1H, J=2.2Hz), 7.66 (m, 2H), 7.55 (d, 1H, J=16.0 Hz), 7.42 (m, 5H), 6.90 (d, 1H, 237 
J=7.9 Hz), 6.52 (m, 2H), 2.42 (m, 6H), 1.69 (m, 1H), 1.50 (m, 4H),1.23 (d, 4H, J=6.3 Hz), 238 
0.91 (t, 6H, J=7.1 Hz); δC (100 MHz, DMSO-d6) 167.8, 151.8, 149.5, 149.2, 143.2, 134.4, 239 
133.3, 130.0, 128.8, 128.0, 127.4, 124.3, 123.8, 120.1, 117.5, 98.8, 51.9, 47.5, 46.1, 33.3, 240 
23.0, 19.8, 11.2 241 
(EI+) m/z calculated for C18H27ClN3
+: 320.19, found 320.33; (EI-) m/z calculated for C9H7O2
- 242 
147.05, found 147.33 243 
2-((7-chloroquinolin-4-yl)amino)-N,N-diethylpropan-1-aminium p-methoxycinnamate 244 
(2’d) 245 
Colorless oil (52 mg, 87%) δH (400 MHz, DMSO-d6) 8.37 (s, 1H), 8.34 (d, 1H, J=4.4Hz), 246 
7.76 (d, 1H, J=2.2Hz), 7.62 (d, 2H, J=8.8 Hz), 7.51 (d, 1H, J=15.9 Hz), 7.42 (dd, 1H, J=9.0 247 
Hz, J= 2.2 Hz), 6.96 (d, 2H, J=8.8Hz), 6.89 (d, 1H, J= 8.0 Hz), 6.50 (d, 1H, J= 5.6 Hz), 248 
6.36 (d, 1H, J= 15.9 Hz), 3.79 (s, 3H), 2.40 (m, 6H) 1.69 (m, 1H), 1.50 (m, 4H), 1.22 (m, 249 
4H), 0.91 (t, 6H, J=7.1 Hz); δC (100 MHz, DMSO-d6) 167.9, 160.8, 151.9, 149.5, 149.3, 250 
143.4, 133.3, 129.8, 127.4, 126.9, 124.3, 123.7, 117.5, 116.9, 114.3, 98.8, 55.3, 52.0, 47.5, 251 
46.1, 33.3, 23.3, 19.8, 11.5 252 
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12 
(EI+) m/z calculated for C18H27ClN3
+: 320.19, found 320.35; (EI-) m/z calculated for C10H9O3
- 253 
177.06, found 177.05 254 
 255 
In vitro assays. Compound preparation. Test compounds were stored at -20 ºC without ex-256 
posure to light, until use. Immediately prior to the first screen, compounds were solubilized 257 
in 100% DMSO at a concentration of 20 mg/mL. For testing, the compounds were diluted 258 
directly into culture medium at dilutions of 100, 10, 1, and 0.1 µg/mL. Culture medium 259 
consisted of RPMI-1640 containing 20% horse serum, 1% MEM vitamin solution, 1% 260 
MEM NEAA, 200 units/mL penicillin and 0.2 mg/mL streptomycin, and 50 µg/mL vanco-261 
mycin. Negative controls were medium alone, and 10 µg/mL ampicillin. Positive control 262 
was 1 µg/mL pentamidine isethionate. Medium with the vehicle alone (DMSO) was tested 263 
at the highest dilution to identify any associated toxicity.  264 
P. carinii ATP assay. P. carinii viability was assessed through a non-specific ATP assay pre-265 
viously validated for this purpose (42-44,48,49). Briefly, cryopreserved and characterized P. 266 
carinii isolated from rat lung tissue was distributed into triplicate wells of 48-well plates 267 
with a final volume of 500 µL and a final concentration of 5×107 nuclei/ml Pj and 5×106 268 
Pm. Controls and compound dilutions were added and incubated at 36 ºC, 5% CO2. At 24, 269 
48, and 72 hours, 10% of the well volume was removed and the ATP content was measured 270 
using Perkin Elmer ATP-liteM luciferin-luciferase assay. The bioluminescence generated by 271 
the ATP content of the samples was measured with a BMG POLARstar OPTIMA spectro-272 
photometer and expressed as Relative Light Units (RLUs). A sample of each group was 273 
examined microscopically on the final assay day to rule out the presence of bacteria or oth-274 
er fungi. A quench control assay to determine compound interference in the lucifer-275 
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13 
in/luciferase revealed quenching with six compounds at the highest (100 µg/mL) concentra-276 
tion. No quench was observed at 50 µg/mL. Test concentrations of these compounds were 277 
lowered accordingly. 278 
L2 and A549 Toxicity assay. For mammalian cell toxicity testing, A549 cells were cultured 279 
in DMEM medium and L2 cells with F12 medium. Both were supplemented with 10% fetal 280 
calf sera, 1× MEM vitamins, and 1X NEAA. Cultured cells were plated at 2×105/mL and 281 
grown to confluent monolayers. Media was removed and replaced with fresh media con-282 
taining controls and test compound in appropriate dilutions.  Assays of three time points 283 
(24, 48, 72 h) with triplicate wells were sampled. Media was aspirated from the wells. Ad-284 
herent cells were stained with MTT reagent (thiazolyl blue) and incubated for one hour. The 285 
MTT reagent was aspirated from the cells and the MTT solvent added to the stained cells 286 
and rocked at room temperature until the crystals were dissolved. The plate was read in 287 
absorbance mode on a BMG POLARstar OPTIMA spectrophotometer. 288 
Calculations. For the P. carinii ATP assay, background bioluminescence was subtracted and 289 
triplicate well readings were averaged. Using EXCEL software, % reduction in ATP for all 290 
groups was calculated (vehicle control - experimental/vehicle control ×100); results of trip-291 
licate assays were averaged and standard deviation determined. For the cell toxicity assay, 292 
triplicate well readings were averaged; for each day’s readings, % reduction in absorbance 293 
for all groups was calculated: media control - experimental/media control ×100. In both 294 
assays, the 50% inhibitory concentration (IC50) was calculated using InSTAT linear regres-295 
sion program. 296 
 297 
Abbreviations 298 
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6GPD, 6-glucose-phosphate dehydrogenase; ATP, adenosine triphosphate; CQ, chloroquine; 299 
DAD, diode array detector; DMEM, Dulbecco’s modified Eagle medium; DMSO, dime-300 
thylsulfoxide; PcP, Pneumocystis carinii pneumonia; HIV, human immunodeficiency virus; 301 
HAART, highly active antiretroviral therapy; HPLC, high performance liquid chromatog-302 
raphy; HRMS, high resolution mass spectrometry; IC50, 50% inhibitory concentration; 303 
MEM, minimum essential medium; MPR, mepacrine; MTT, 3-(4,5-dimethylthiazol-2-yl)-304 
2,5-diphenyltetrazolium bromide; NEAA, non-essential amino acid solution; NMR, nuclear 305 
magnetic resonance; PEG, polyethyleneglycol; PiRBC, Plasmodium-infected erythrocytes; 306 
PQ, primaquine; SD, standard deviation; SI, selectivity index; TBTU, 2-(1H-Benzotriazole-307 
1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate; TMP-SMX, trime-308 
thoprim/sulfamethoxazole; TMS, tetramethylsilane; RPMI, Roswell Park Memorial Insti-309 
tute medium. 310 
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Figure 1. Classical antimalarial drugs and respective analogues, herein under scrutiny as 470 
potential anti-Pneumocystis agents. 471 
  472 
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 473 
 474 
Figure 2. Correlation between in vitro anti-Pneumocystis activity (IC50 at 72 h / M) of 475 
compounds 2a-e and Hammett constants para for the aryl substituent group R. 476 
 477 
 478 
 479 
 480 
 481 
 482 
 483 
 484 
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Table 1. Minimal inhibitory concentrations at 50% (IC50) of test compounds, at 72 h, 486 
against P.carinii, A549 human lung adenocarcinoma cells, and L2 rat pulmonary epithelial 487 
cells. IC50 values both in M and in g/mL units (the latter, within parenthesis). 488 
Cpd 
IC50 ± SD / M (IC50 ± SD / g/mL) 
SI1(c) SI2(d) 
P. carinii(a) A549 cells(b) L2 cells(b) 
1 
4.92 ± 0.85  
(1.28 ± 0.221) 
110.04 ± 49.93  
(28.5 ± 13.0) 
>200  
(>100) 
22.4 >41 
1a 
43.58 ± 3.14  
(16.97 ± 1.22) 
>200  
(>100) 
>200  
(>100) 
>5 >5 
1b 
35.42 ± 7.52  
(14.86± 3.16) 
>200  
(>100) 
>200  
(>100) 
>6 >6 
1’a 
5.17 ± 4.46  
(2.11 ± 1.82) 
120.49 ± 43.56 
(49.1 ± 17.8) 
>200  
(>100) 
23.3 >39 
1’b 
5.09 ± 1.11  
(2.23 ± 0.486) 
100.15 ± 41.53  
(43 ± 18.2) 
>200  
(>100) 
19.7 >39 
2 
3.13 ± 2.14  
(1.00± 0.685) 
61.55 ± 6.38  
(19.7 ± 2.04) 
>200  
(>100) 
19.7 >64 
2a 
4.34 ± 1.34  
(1.65 ± 0.509) 
19.01 ± 14.29  
(7.22 ± 5.43) 
82.84 ± 7.27 
(31.5 ± 2.76) 
4.38 4.36 
2b 
1.85 ± 2.75  
(0.730 ± 1.08) 
>200  
(>100) 
>200  
(>100) 
>100 >100 
2c 
2.75 ± 2.30  
(1.16 ± 0.971) 
12.94 ± 6.99  
(5.46 ± 2.95) 
75.01 ± 16.35 
(31.6 ± 6.90) 
4.71 5.80 
2d 
1.45 ± 0.06  
(0.593 ± 0.023) 
80.02 ± 46.11  
(32.8 ± 18.9) 
128.59 ± 72.75 
(52.7 ± 29.8) 
55.3 1.61 
2e 
5.81 ± 2.19  
(2.41 ± 0.906) 
17.79 ± 12.41  
(7.37 ± 5.14) 
48.13 ± 23.48 
(19.9 ± 9.73) 
3.06 2.71 
2f 
4.09 ± 3.21  
(1.55 ± 1.22) 
41.04 ± 14.85  
(15.6 ± 5.64) 
139.62 ± 17.98 
(53.0 ± 6.83) 
10.0 3.40 
2g 
2.61 ± 0.80  
(1.10 ± 0.340) 
51.68 ± 30.19  
(21.9 ± 12.8) 
79.26 ± 50.24 
(33.6 ± 21.3) 
19.8 1.53 
2h 
>200  
(>100) 
- - - - 
2i 
7.00 ± 1.06  
(2.70 ± 0.411) 
>200  
(>100) 
>200  
(>100) 
>29 >29 
2j 
8.45 ± 2.58  
(2.79 ± 0.850) 
166.60 ± 53.27  
(55.0 ± 17.6) 
>200  
(>100) 
19.7 >24 
2’a 
4.99 ± 1.64  
(2.34 ± 0.769) 
65.74 ± 7.84  
(30.8 ± 3.67) 
>200  
(>100) 
13.2 >40 
2’d 4.60 ± 2.39  59.23 ± 22.19  >200  12.9 >43 
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(2.29 ± 1.19) (29.5 ± 11.0) (>100) 
3 
0.90 ± 0.21  
(0.358 ± 0.083) 
17.58 ± 1.50  
(7.03 ± 0.600) 
124.19 ± 11.45 
(49.7 ± 4.58) 
19.6 7.07 
3a 
2.27 ± 0.50  
(1.11 ± 0.245) 
72.04 ± 60.20  
(35.3 ± 29.5) 
>200  
(>100) 
31.7 >88 
 
489 
(a) Activity scale: high, <0.010 g/mL; very marked, 0.011 to 0.099 g/mL; marked, 0.10 to 490 
0.99 g/mL; moderate, 1.0 to 9.99 g/mL; slight, 10.0 to 49.9 g/mL; none, ≥ 50 491 
g/mL.(24,25) (b) Cytotoxicity scale: high, < 1 g/mL; moderate, 1.1 to 10 g/mL; mild, 492 
10.1 to 99.9 g/mL; none, ≥ 100 g/mL.(24,25) SI = selectivity index, where  (c)SI1 = 493 
IC50(A549) / IC50(P. carinii), and 
(d) SI2 = IC50 (L2) / IC50 (P. carinii). 494 
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